摘要
促血管生成素(angiopoietins,ANGPT)及其受体TEK是新发现在机体的生理、病理性血管形成中发挥重要调节作用的信息途径。生理情况下,ANGPT1激活TEK受体,促进血管生成、维持血管完整稳定;ANGPT2则竞争性拮抗ANGPT1的作用,当血管内皮生长因子存在时,可促进血管重建,血管内皮生长因子缺乏时,则促进血管退化。肿瘤发生时,ANGPT及TEK受体在肿瘤组织中表达明显增高,特别是ANGPT2特异表达于肿瘤新生血管区,参与肿瘤血管新生的起始及延续过程。阻断ANGPT及TEK信号传导途径可抑制肿瘤生长,有望为肿瘤的临床治疗提供一种新途径。
Angiopoietins（ANGPF） and their endothelial cell-specific tyrosine kinase receptors TEK are the major regulators of blood vessels angiogenesis under physiological and pathologic conditions. ANGPT1 is essentially involved in maturation, stabilization, and remodefing of blood vessels through inducing TEK autophosphorylation, promoting endothehal cell migration and survival, Instead, ANGPT2 appears to act as a natural antagonist of ANGPT1, it can activate vascular remodeling with the presence of vascular endothelial growth faetor（VEGF） or regress frank blood vessels under the absence of VEGF. High expression of angiopoietins and TEK is often detected in tumor tissues. Many studies showed that disrupting the ANGPT/TEK receptor pathway could inhibit the growth of a number of murine tumors and human tumors. Thus, it is possible that inhibitors targeting the ANGFF/TEK pathway will have broad clinical utility to treatment of cancer.
出处
《中华医学遗传学杂志》
CAS
CSCD
北大核心
2006年第1期63-66,共4页
Chinese Journal of Medical Genetics
基金
国家自然科学基金(30130260)~~
